Video

Dr Han on the Investigation of Gedatolisib in HR+/HER2– Metastatic Breast Cancer

Author(s):

Heather Han, MD, discusses prior research with gedatolisib that provided the rationale for the phase 3 VIKTORIA-1 trial (NCT05501886) in patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Heather Han, MD, research director, Department of Breast Oncology, Moffitt Cancer Center, discusses prior research with gedatolisib that provided the rationale for the phase 3 VIKTORIA-1 trial (NCT05501886) in patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Patients with HR-positive, HER2-negative, metastatic breast cancer have effective frontline treatment options, including endocrine therapy combined with a CDK4/6 inhibitor, Han says. However, these patients often progress on or after their first-line treatment because of acquired resistance to endocrine therapy or CDK4/6 inhibitors, prompting investigations of more effective first- or second-line treatments that may overcome these resistance issues, Han explains.

Previously, a phase 1b study (NCT02684032) explored the clinical activity of gedatolisib, a dual small molecule inhibitor of PI3K and mTOR, in combination with the CDK4/6 inhibitor palbociclib (Ibrance) and the endocrine therapy fulvestrant (Faslodex), in patients with HR-positive, HER2-negative, advanced breast cancer with prior exposure to a CDK4/6 inhibitor. This triplet combination led to a median progression-free survival of 12.9 months in the second-line setting and an overall response rate of 63% in this population, regardless of PIK3CA mutation status.

Additionally, the combination was well tolerated, with 1 patient discontinuing treatment at the phase 3 dosing schedule because of treatment-related adverse effects (AEs). The incidence of grade 3/4 AEs typically associated with PI3K/mTOR inhibitors was low. In total, 7%, 6%, and 4% of patients experienced grade 3/4 hyperglycemia, diarrhea, and aspartate aminotransferase/alanine transaminase increase, respectively.

Based on the response rates and safety profile seen in this phase 1b trial, the registrational VIKTORIA-1 trial was designed, Han emphasizes. In this multinational trial, patients with HR-positive, HER2-negative, advanced breast cancer with prior exposure to a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor will be stratified by PIK3CA mutation status. Patients with PIK3CAmutations will be randomized to receive gedatolisib plus palbociclib and fulvestrant; alpelisib (Piqray) plus fulvestrant; or gedatolisib plus fulvestrant. Patients without PIK3CA mutations will be randomized to receive gedatolisib plus palbociclib and fulvestrant; gedatolisib plus fulvestrant; or fulvestrant alone.

Disclosures: Dr Han reports grants from/contracts with AbbVie, GSK, G1 Therapeutics, Quantum Leap Healthcare Collaborative, Pfizer, Zymeworks, Department of Defense, Arvinas, Celcuity, and Marker; consulting fees from Eli Lilly; institutional research funding from Mersana Therapeutics; and data safety monitoring board/advisory board roles with Novartis, AstraZeneca, and Gilead.

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS